CTLA4 and neoplasm: Furthermore, since the novel antibodies do not induce the degradation of CTLA-4, they could provide safe and more efficient anti-tumor responses, differently from those antibodies that trigger degradation of CTLA-4 increasing the toxicity and reducing anti-tumor efficacy, as previously reported [39].